PE
CRNX icon

Point72 Europe’s Crinetics Pharmaceuticals CRNX Stock Holding History

Point72 Europe’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$5.05K Buy
+121
New +$3.87K ﹤0.01% 601

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Point72 Europe's CRNX Position: Q3 2025 in Review

Point72 Europe opened a new position in Crinetics Pharmaceuticals (CRNX) in Q3 2025: 121 shares worth $5.05K. The stake represents ﹤0.01% of the portfolio and ranks #601 among its holdings.

225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

  • Point72 Europe held 121 shares of Crinetics Pharmaceuticals worth $5.05K as of Q3 2025.
  • Crinetics Pharmaceuticals was a new Point72 Europe position in Q3 2025.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #601 holding.
  • 225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.